TYRA BIOSCIENCES INC
TYRANASDAQTrading Snapshot
- Day Range
- $21.77 – $22.14
- 52-Week Range
- $12.40 – $40.65
- Volume
- $2.22B
- Avg Volume
- $2.53B
- Shares Outstanding
- 59.5M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $107M
- Last Q Revenue
- $28M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.39
- Dividend Yield
- —
- Dilution (1yr)
- +1.2%
Why Investors Own TYRA
- ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TYRA BIOSCIENCES INC
TYRA
StockOtter · stockotter.spaceAbout TYRA BIOSCIENCES INC
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA). Such investors are advised to contact Daniell
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the stock, Marketbeat reports. One investment analys
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and ident
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.